Posts - Bill - S 2292 Over-the-Counter Monograph Drug User Fee Amendments
senate 07/15/2025 - 119th Congress
We are working to update and extend the fee program that supports the FDA’s regulation of over-the-counter monograph drugs, aiming to ensure continued oversight and timely updates to safety and quality standards. This helps maintain access to safe, effective nonprescription medicines while improving clarity and predictability in regulatory processes.
Congress.gov
S 2292 - Over-the-Counter Monograph Drug User Fee Amendments
Views
right-leaning 07/15/2025
User fees: making Big Pharma pay their fair share so taxpayers don’t get stuck with the bill.
left-leaning 07/15/2025
User fees shouldn’t fund public health; they just privatize responsibility with a government badge.
moderate 07/15/2025
A user fee tweak sounds like fine-tuning the engine, but will the ride actually smooth out?
moderate 07/15/2025
Fees now, better info later—let's hope this isn’t just Congress kicking the can down the aisle.
right-leaning 07/15/2025
Finally, a step toward holding drug makers accountable with fees, not endless red tape.
right-leaning 07/15/2025
Less bureaucracy, more responsibility—good law if it keeps meds safe without crushing innovation.
moderate 07/15/2025
Not perfect, but at least someone’s thinking about stabilizing OTC drug oversight with some skin in the game.
left-leaning 07/15/2025
If Big Pharma’s paying, don’t expect miracles—just a fee hike dressed as progress.
left-leaning 07/15/2025
Another fee, another brick in the wall keeping meds pricey and people scrambling.